The biotech JPMorgan Chase & Co (JPM) stock has been recommended by Hosking Partners as a top buy. It took a significant leap to an all-time high of $223.68 recently. With the Q4 earnings preview, JPMorgan was heralded among 'Top Fintech Picks' with an attractive entry point. The asset management division of JPMorgan has forecasted stocks to power through the second half. Despite the upward momentum, JPMorgan cut Kohl’s stock rating based on forecasted sales and EPS outlook. Further, it articulates potential crowding in the stocks arena that could lead to an abrupt downturn. A cut in Marathon Digital stock target has also been noted by JPMorgan. Amid these considerations, there’s a proposition of the stock market moving towards higher concentration. Finally, amid potential fears about the CEO’s retirement, JPMorgan insiders continue to place their faith in existing US stocks. Despite modest falls, JPMorgan shares continue to carry growth potential. Lastly, forecasts imply an upcoming dip opportunity and strategists hint that stocks may ignore future rate cuts.
Jpmorgan Stocks News Analytics from Wed, 13 Dec 2023 08:00:00 GMT to Sat, 31 Aug 2024 10:34:56 GMT - Rating 5 - Innovation 0 - Information 7 - Rumor -2
